Compare forecasts

Two records, side by side.

Read the registered questions at a shared date. Each keeps its own deadline and the rule that settles it. This is not a ranking: a higher probability describes a different estimate.

Each line starts at registration and ends at its own deadline. The coral marker is the selected date.
FF-011
FF-001
As of Nov 21, 2026

FDAFF-011

Ivonescimab · post-TKI NSCLC approval

15%Registered probability

At this date the deadline had passed; the outcome had not yet been read.

Action by
Evidence as of
Registered
State at this date
Deadline passed; outcome can be checked from Nov 28, 2026
Read the registered question and rule

The FDA takes an approval action on a Biologics License Application for ivonescimab (applicant Summit Therapeutics) for EGFR-mutated non-small cell lung cancer previously treated with an EGFR tyrosine kinase inhibitor, with an approval action date on or before 2026-11-14, the PDUFA goal action date disclosed in Summit Therapeutics' Form 8-K filed 2026-09-15.

Resolution rule

Resolves YES if the openFDA Drugs@FDA record returned by https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22ivonescimab%22 contains an application whose ORIG submission has submission_status AP and a submission_status_date on or before 2026-11-14, and the Drugs@FDA approval letter or label for that application names in its indication EGFR-mutated (EGFR mutation-positive) non-small cell lung cancer that was previously treated with, or progressed on or after, an EGFR tyrosine kinase inhibitor. An approval for a narrower population than the applicant sought (for example non-squamous disease only, or only after a third-generation EGFR tyrosine kinase inhibitor) still resolves YES, as does an approval under accelerated approval. Resolves NO if no approval action is dated on or before 2026-11-14: a complete response letter, a goal-date extension, withdrawal or no action. The goal date is frozen as disclosed at the cutoff; a later extension does not move it, and an approval dated after 2026-11-14 resolves NO as occurred_after_deadline. 2026-11-14 is a Saturday; an approval action dated that day still counts. Read no earlier than 2026-11-28. If openFDA has not refreshed by then, the Drugs@FDA web record (https://www.accessdata.fda.gov/scripts/cder/daf/, searched by the name ivonescimab) governs, and if neither lists the product, FDA's Purple Book (https://purplebooksearch.fda.gov/, searched by ivonescimab) governs for the licensure date, with the approval letter for the indication. The application number was not public at the cutoff, so the rule reads by name; a four-letter suffix on the nonproprietary name (ivonescimab-xxxx) or a proprietary name does not change the identification. At the cutoff ivonescimab was not approved in the United States (SRC-001). Resolves unresolvable only if none of these sources can be read after the read floor. Resolves VOID, with the reason recorded, only if FDA withdraws every public record of approval actions named above without an equivalent public successor, so that no approval date for this product can be read; while any of them publishes it, the rule stands.

Regulatory action (FDA): offered on judgment, with no calibration figure until 15 in the class have resolved.

Read the full record

NCCNFF-001

Sunvozertinib · first-line guideline listing

75%Registered probability

At this date the record was registered at 75% and the deadline had not been reached. The outcome was not yet knowable.

Action by
Evidence as of
Registered
State at this date
Unresolved
Read the registered question and rule

A version of the NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer carrying a version date on or before 2027-07-31 lists sunvozertinib (ZEGFROVY) as a first-line / initial systemic therapy option, at any NCCN category, for EGFR exon 20 insertion mutation-positive metastatic non-squamous NSCLC.

Resolution rule

Resolves YES if any NCCN NSCLC guideline version dated on or before 2027-07-31 names sunvozertinib (or ZEGFROVY) anywhere in the initial-systemic-therapy recommendation set for EGFR exon 20 insertion mutation-positive metastatic non-squamous NSCLC, at any category (1, 2A, 2B, or 3) and whether or not it is marked preferred. The adjudicator reads the NSCLC algorithm page for initial systemic therapy in EGFR exon 20 insertion mutation-positive disease and the corresponding systemic therapy tables, in the latest version dated on or before 2027-07-31. Resolves NO if no such version names it there. Listing confined to subsequent-line or post-progression therapy does NOT count. Access requires free NCCN registration; no clinical judgement about the drug is needed to apply this rule.

Guideline listing (NCCN, ESMO): offered on judgment, with no calibration figure until 15 in the class have resolved.

Read the full record

The estimate stays frozen. A new assessment creates another registration; moving the date here does not create a probability history. How a forecast is registered and scored.

Registry snapshot . Return to all registered forecasts.